mTOR inhibition and adult T-cell leukemia

Leukemia and Lymphoma

Volumn 50, Issue 4, 2009, Pages 645-647

  Hirase, Chikara ^a   Maeda, Yasuhiro ^a   Yamaguchi, Terufumi ^a   Miyatake, Jun Ichi ^a   Kanamaru, Akihisa ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RAPAMYCIN;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG TARGETING; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN T CELL LEUKEMIA VIRUS 1; LEUKEMIA CELL LINE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T CELL LEUKEMIA;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADULT; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; CELL PROLIFERATION; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; JURKAT CELLS; LEUKEMIA-LYMPHOMA, ADULT T-CELL; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; SIROLIMUS; TIME FACTORS;

EID: 68449093184     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190802709446     Document Type: Article

References (11)

1. Uchiyama T, Yodoi J, Sagawa K, Takatsuki K, Uchino H. Adult T-cell leukemia: Clinical and hematologic features of 16 cases. Blood 1977;50:481-492.
2. Hinuma Y, Nagata K, Hanaoka M, Nakai M, Matsumoto T, Kinoshita K, et al. Adult T-cell leukemia: Antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc Natl Acad Sci USA 1981;78:6476-6480.
3. Shimoyama M. Treatment of patients with adult T-cell leukemia-lymphoma: an overview, In: Takatsuki K, Hinuma Y, Yoshida M (eds). Advances in Adult T-Cell Leukemia and HTLV-1 Research. Vol. 39. Tokyo, Japan: Scientific Societies Press; 1992. pp 43-56.
4. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006;124:471-484.
5. Majumber PK, Febbo PG, Bikoff R, Berger R, Xue Q, Sellers WR, et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 2004;10:594-601.
6. Gingras AC, Raught B, Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev 2001;15:807-826.
7. Burchert A, Wang Y, Cai D, von Bubnoff N, Paschka P, Neubauer A, et al. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development. Leukemia 2005;19:1774-1782.
8. Huang S, Houghton PJ. Targeting mTOR signaling for cancer therapy [review]. Curr Opin Pharmacol 2003;3:371-377.
9. Hirase C, Maeda Y, Takai S, Kanamaru A. Hypersensitivity of Ph-positive lymphoid cell lines to rapamycin; possible clinical application of mTOR inhibitor. Leukemia Res 2009;33:450-459.
10. Ikezoe T, Nishioka C, Bandobashi K, Yang Y, Kuwayama Y, Taguchi H, et al. Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells. Leukemia Res 2007;31:673-682.
11. Berridge MV, Tan AS. Characterization of the cellular reduction of 3-(4, 5-dimethylthiazol-2-yl)- 2,5-diphenyltetrazolium bromide (MTT): subcellular localization, substrate dependence, and involvement of mitochondrial electron transport in MTT reduction. Arch Biochem Biophys 1993;303:474-482.